Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AMG 333 · 1 trial · 1 indication
Treatment-emergent adverse events, including changes in vital signs, 12-lead ECGs, clinical laboratory safety tests, and physical and neurological assessments
| Arm | Type | Description |
|---|---|---|
| AMG 333 | EXPERIMENTAL | Subjects will receive a single oral dose of AMG 333 . |
| Placebo | PLACEBO_COMPARATOR | Subjects will receive a single oral dose of placebo. |
| Name | Type | Description |
|---|---|---|
| AMG 333 | DRUG | Oral administration available in varying dose strength. |
| Placebo | DRUG | Placebo containing no active drug |
Inclusion Criteria: * Healthy male and female subjects with or without migraines ≥18 and ≤55 years of age at the time of screening, with no history or evidence of clinically relevant medical disorders as determined by the investigator in consultation with the Amgen physician. Exclusion Criteria: ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 13 | PHASE3 | Atogepant |
| Pfizer Inc. | PFE | 9 | PHASE3 | Rimegepant |
| Eli Lilly and Company | LLY | 2 | PHASE3 | Galcanezumab |
| Amgen Inc. | AMGN | 2 | PHASE3 | Erenumab Dose 1 |
| Ki Health Partners. LLC | RVNC | 1 | - | Daxibotulinumtonix A |
AMG 333 is an investigational small molecule being developed for the treatment of migraine. It is a neurology therapeutic that has been studied in a Phase 1 clinical trial. The drug is not approved and remains in clinical development.
AMG 333 is being developed by Amgen Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol AMGN. The company conducted a Phase 1 study of the drug in healthy subjects and subjects with migraines.
AMG 333 is in Phase 1 clinical development. It has completed a single-ascending dose study, and no active trials are currently listed. The drug is investigational and has not been approved by regulatory authorities.
AMG 333 has been studied in one completed Phase 1 trial, NCT01953341, titled 'Single-Ascending Dose Study of AMG 333 in Healthy Subjects and Subjects With Migraines.' The trial enrolled 74 participants in the United States and was randomized, double-blind, and placebo-controlled.
AMG 333 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial. The drug is still in clinical development, and its safety and efficacy have not been established for regulatory approval.